Who Exports Antitoxin from India — 45 Suppliers Behind a $13.3M Market
India's antitoxin export market is supplied by 45 active exporters who collectively shipped $13.3M across 524 shipments. VINS BIOPRODUCTS LIMITED leads with a 64.7% market share, followed by PREMIUM SERUMS AND VACCINES PRIVATE LIMITED and SERUM INSTITUTE OF INDIA PRIVATE LIMITED. The top 5 suppliers together control 91.1% of total export value, reflecting a concentrated market structure.
Top Antitoxin Exporters from India — Ranked by Export Value
VINS BIOPRODUCTS LIMITED is the leading antitoxin exporter from India, holding a 64.7% share of the $13.3M market across 524 shipments from 45 exporters. The top 5 suppliers — VINS BIOPRODUCTS LIMITED, PREMIUM SERUMS AND VACCINES PRIVATE LIMITED, SERUM INSTITUTE OF INDIA PRIVATE LIMITED, BIOLOGICAL E. LIMITED, VINS BIOPRODUCTS LTD — collectively control 91.1% of total export value, indicating a highly concentrated market. Individual shares are: VINS BIOPRODUCTS LIMITED (64.7%), PREMIUM SERUMS AND VACCINES PRIVATE LIMITED (10.1%), SERUM INSTITUTE OF INDIA PRIVATE LIMITED (7.5%), BIOLOGICAL E. LIMITED (6.0%), VINS BIOPRODUCTS LTD (2.8%).
Top Antitoxin Exporters from India
Ranked by export value · 45 active suppliers · Indian Customs (DGFT) data
| # | Supplier & Formulations | Value | Ctry. | Share |
|---|---|---|---|---|
| 1 | VINS BIOPRODUCTS LIMITED TETANUS ANTITOXIN IHS/BP 1500 IU/MLTETANUS ANTITOXIN 1500 IU IP PFS (TETAVIANTITOXINE TETANIQUE 1500 UI BP SOLUTION (FOC | $8.6M | 37 | 64.7% |
| 2 | PREMIUM SERUMS AND VACCINES PRIVATE LIMITED TETANUS ANTITOXIN 1500 IU IP PFS (TETAVIDIPHTHERIA ANTITOXIN 1000/IUML, 10ML VIALSTETANUS ANTITOXIN 1500 IU PFS | $1.4M | 19 | 10.1% |
| 3 | SERUM INSTITUTE OF INDIA PRIVATE LIMITED TETANUS ANTITOXIN 1500 IU IP PFS (TETAVIDIPHTHERIA ANTITOXIN 1000/IUML, 10ML VIALSTETANUS ANTITOXIN 1500 IU PFS | $999.9K | 23 | 7.5% |
| 4 | BIOLOGICAL E. LIMITED TETANUS ANTITOXIN 1500 IU IP PFS (TETAVIDIPHTHERIA ANTITOXIN 1000/IUML, 10ML VIALSTETANUS ANTITOXIN 1500 IU PFS | $805.0K | 10 | 6.0% |
| 5 | VINS BIOPRODUCTS LTD TETANUS ANTITOXIN IHS/BP 1500 IU/MLTETANUS ANTITOXIN 1500 IU IP PFS (TETAVIANTITOXINE TETANIQUE 1500 UI BP SOLUTION (FOC | $373.1K | 7 | 2.8% |
| 6 | BIOLOGICAL E LIMITED TETANUS ANTITOXIN 1500 IU IP PFS (TETAVIDIPHTHERIA ANTITOXIN 1000/IUML, 10ML VIALSTETANUS ANTITOXIN 1500 IU PFS | $293.2K | 4 | 2.2% |
| 7 | PREMIUM SERUMS VACCINES PVT LTD TETANUS ANTITOXIN 1500 IU IP PFS (TETAVIDIPHTHERIA ANTITOXIN 1000/IUML, 10ML VIALSTETANUS ANTITOXIN 1500 IU PFS | $276.2K | 3 | 2.1% |
| 8 | PREMIUM SERUMS VACCINES PRIVATE LIMITED TETANUS ANTITOXIN 1500 IU IP PFS (TETAVIDIPHTHERIA ANTITOXIN 1000/IUML, 10ML VIALSTETANUS ANTITOXIN 1500 IU PFS | $157.2K | 5 | 1.2% |
| 9 | PRAGCURE HEALTHCARE PRIVATE LIMITED | $96.9K | 3 | 0.7% |
| 10 | FLAGSHIP BIOTECH INTERNATIONAL PRIVATE LIMITED | $53.7K | 1 | 0.4% |
| 11 | REDWING PHARMA PRIVATE LIMITED | $49.5K | 1 | 0.4% |
| 12 | MODERN DRUG HOUSE SNAKE VENOM ANTITOXIN LYOPHILFOR SNAKE VENOM ANTITOXIN I.H.S- BISNAKEDIPHTHERIA ANTITOXIN 10,000 IU BP-50 VIA | $38.6K | 4 | 0.3% |
| 13 | JPC GLOBAL | $31.5K | 3 | 0.2% |
| 14 | PHARMA CHOICE LLP SNAKE VEOM ANTITOXIN LYOPHILIZEDSNAKE VENOM ANTITOXIN LYOPHILTETANUS ANTITOXIN 1500 IU INJECTION (1ML | $22.5K | 2 | 0.2% |
Related Analysis
Supplier Certification & Compliance Matrix
FDA, WHO-GMP, and EU GMP status for top Antitoxin exporters
| Supplier | US FDA | WHO-GMP | EU GMP | ANDAs | Notes |
|---|---|---|---|---|---|
| PREMIUM SERUMS AND VACCINES PRIVATE LIMITED | Not Listed | Yes, as of December | No | Not verified | WHO-GMP certification confirmed by CDSCO on December 1, 2022. |
| FLAGSHIP BIOTECH INTERNATIONAL PRIVATE LIMITED | Not Listed | Yes, as of December | No | Not verified | WHO-GMP certification confirmed by CDSCO on December 1, 2022. |
TransData Nexus reviewed the regulatory standing of 2 leading Antitoxin exporters from India. 0 hold US FDA facility approvals, 2 maintain WHO-GMP certification, and 0 are EU GMP compliant. For regulated markets (US, EU, Australia), prioritise suppliers with active FDA or EU GMP approvals. For semi-regulated markets (Africa, ASEAN, Latin America), WHO-GMP certification is the minimum recommended standard.
Certification status compiled from publicly available regulatory databases including FDA Orange Book, WHO Prequalification database, and EMA GMP registry. Buyers should independently verify compliance status with the relevant regulatory authority before placing orders.
TransData Nexus Research · Mar 2026
Manufacturing Hub Analysis — Vendor Proximity
India's pharmaceutical clusters relevant to Antitoxin sourcing
1Hyderabad — Bulk Drug Capital
Hyderabad, often referred to as the "Bulk Drug Capital of India," is a major hub for the production of active pharmaceutical ingredients (APIs) and vaccines. The city hosts Genome Valley, India's first biotech cluster, which is home to numerous pharmaceutical companies specializing in biologics and biosimilars. Notably, Biological E. Limited, headquartered in Hyderabad, is a significant player in vaccine production. The city's robust infrastructure and skilled workforce make it a critical center for pharmaceutical manufacturing.
2Ahmedabad-Vadodara — Formulations Hub
The Ahmedabad-Vadodara corridor in Gujarat is renowned for its focus on pharmaceutical formulations and finished dosage forms. This region contributes nearly 28% of India's pharmaceutical production and houses major companies like Zydus Lifesciences and Cadila Pharmaceuticals. The well-established infrastructure, coupled with a strong regulatory framework, positions this cluster as a leader in the production of generic drugs and complex formulations.
3Mumbai-Thane-Raigad — Export Gateway
The Mumbai-Thane-Raigad region serves as a pivotal export gateway for India's pharmaceutical industry. Mumbai, being a major port city, facilitates the export of pharmaceutical products to various international markets. The region is home to several multinational pharmaceutical companies and offers a strategic advantage due to its proximity to global shipping routes. This cluster's emphasis on compliance with international regulatory standards ensures the quality and efficacy of exported pharmaceuticals.
4Baddi-Nalagarh — Tax Incentive Zone
Baddi-Nalagarh in Himachal Pradesh has emerged as a significant pharmaceutical manufacturing hub, primarily due to favorable tax incentives and government policies. The region hosts over 1,000 pharmaceutical units, including major players like Cipla and Dr. Reddy's Laboratories. Baddi's strategic location and cost-effective production capabilities make it an attractive destination for pharmaceutical manufacturing.
5Sourcing Recommendations
- Diversify Supplier Base: Given that VINS Bioproducts Limited accounts for 64.7% of antitoxin exports, it's advisable to diversify sourcing to mitigate risks associated with supplier concentration.
- Evaluate Supplier Capabilities: Assess the manufacturing capabilities and compliance records of potential suppliers in the Hyderabad and Ahmedabad-Vadodara clusters, focusing on their experience with antitoxin production.
- Leverage Export Infrastructure: Utilize the export facilities in the Mumbai-Thane-Raigad region to streamline logistics and ensure timely delivery to international markets.
- Monitor Regulatory Compliance: Ensure that selected suppliers adhere to international regulatory standards, such as those set by the FDA and WHO, to maintain product quality and facilitate market access.
By strategically engaging with these pharmaceutical clusters and adhering to the outlined recommendations, TransData Nexus can optimize its supply chain for antitoxin products, ensuring reliability and compliance in its sourcing strategy.
Recent M&A, Collaborations & Capacity Expansions
Industry developments among top Antitoxin exporters from India
Serum Institute of India Private Limited — Serum Institute partners with Bavarian Nordic for chikungunya vaccine manufacturing
Serum Institute of India (SII) expanded its strategic partnership with Bavarian Nordic to include a contract manufacturing agreement for the chikungunya vaccine. This agreement involves a full technology transfer to SII, enabling the scaling of vaccine production for supply to low- and middle-income countries. - IMPACT: This collaboration is expected to enhance SII's production capabilities, potentially increasing its capacity to manufacture antitoxins and other vaccines for global distribution.
Impact: This collaboration is expected to enhance SII's production capabilities, potentially increasing its capacity to manufacture antitoxins and other vaccines for global distribution.
Common Questions — Antitoxin Suppliers from India
Answers based on Indian Customs (DGFT) shipment records compiled by TransData Nexus
Q Which antitoxin supplier from India is the most reliable for bulk orders?
Based on shipment frequency and export consistency, VINS BIOPRODUCTS LIMITED leads with 206 recorded shipments worth $8.6M. PREMIUM SERUMS AND VACCINES PRIVATE LIMITED (71 shipments) and SERUM INSTITUTE OF INDIA PRIVATE LIMITED (62 shipments) are also established high-volume exporters.
Q How many antitoxin manufacturers are there in India?
India has 45 active antitoxin exporters with a combined export market of $13.3M across 524 shipments to 80 countries. The top 5 suppliers hold 91.1% of total export value.
Q What certifications should I verify?
Verify: WHO-GMP certification (most markets), US FDA approval (United States), EU GMP certificate (EU/EEA), and Free Sale Certificate from CDSCO. Always request a Certificate of Analysis (CoA) and Certificate of Origin (CoO).
Q What is the typical price range for antitoxin from India?
Average FOB unit price: $15.43 per unit, ranging from $0.00 to $102.72. Average shipment value: $25.5K.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Supplier Ranking: 45 verified Indian exporters of Antitoxin ranked by capped export value from DGFT shipping bill records.
- 2.Export Value Analysis: Total export value aggregated from 524 individual shipping bill records. Values are FOB in USD.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation.
- 4.Market Concentration: Supplier market share and geographic reach analyzed across 80 destination countries.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
524 Verified Shipments
45 exporters tracked
Expert-Reviewed
By pharmaceutical trade specialists